There is extreme variability in the expression of ADPKD both between and within families. The factors contributing to these differences are largely unknown, but could be used to predict and potentially alter the clinical outcome of PKD mutations. The between-family variability could be due to locus heterogeneity, to allelic heterogeneity for mutations or wild-type alleles, and/or modifier genes. The within-family variability cannot be explained by either locus heterogeneity or by allelic heterogeneity for mutations, but could be due to allelic heterogeneity for wild-type PKD alleles or modifier genes. This study will use a large collection of clinically well-characterized ADPKD families to determine the effects of wild-type PKD alleles and modifier genes on phenotypic expression. Evidence supporting a 2-hit model of cystogenesis involving a somatic mutation in the wild-type and a distinct pattern of familial correlations for phenotypes relating to the timing and development of cysts, suggest a model in which different wild-type PKD alleles are associated with different somatic mutation rates. The model will be tested in Specific Aim 1 by determining if siblings who inherit the same wild-type PKD allele are more similar than siblings who inherit a different wild-type PKD allele. If so, association studies will be used to identify the specific wild-type PKD allele(s) that have a high somatic mutation rate(s). The pattern of familial correlations for other clinically-relevant ADPKD- related phenotypes, such as creatinine clearance, age at ESRD, and hypertension is consistent with the effects of modifier genes. However, the number of candidate modifier genes among known genes is very large; and one or more as yet unidentified genes could also be involved. Therefore, in Specific Aim 2, a genome screen for linkage will be used to identify positional candidate modifier genes, focusing initially on a subset of the most highly discordant families, followed by replication in families with severe phenotypes. Additional markers in regions where significant linkage is found in both samples will then be typed in all families in order to pinpoint the specific modifier gene(s). A final analysis will be performed to estimate the relative influence of different sources of phenotypic variability, and to investigate the genetic and environmental correlations among different phenotypes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK034039-17
Application #
6604754
Study Section
Special Emphasis Panel (ZDK1)
Project Start
2002-07-01
Project End
2003-06-30
Budget Start
Budget End
Support Year
17
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Perrone, Ronald D; Mouksassi, Mohamad-Samer; Romero, Klaus et al. (2017) Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep 2:442-450
Perrone, Ronald D; Mouksassi, Mohamad-Samer; Romero, Klaus et al. (2017) A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep 2:451-460
Nowak, Kristen L; Cadnapaphornchai, Melissa A; Chonchol, Michel B et al. (2016) Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol 44:171-8
Schrier, Robert W; Abebe, Kaleab Z; Perrone, Ronald D et al. (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371:2255-66
Helal, Imed; Reed, Berenice; Mettler, Pamela et al. (2012) Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease. Am J Nephrol 36:362-70
Reed, Berenice Y; Masoumi, Amirali; Elhassan, Elwaleed et al. (2011) Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int 79:128-34
Helal, Imed; Reed, Berenice; McFann, Kim et al. (2011) Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6:2439-43
Reed, Berenice; McFann, Kim; Kimberling, William J et al. (2008) Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am J Kidney Dis 52:1042-50
Reed, Berenice Y; McFann, Kim; Bekheirnia, Mir R et al. (2008) Variation in age at ESRD in autosomal dominant polycystic kidney disease. Am J Kidney Dis 51:173-83
Tao, Yunxia; Zafar, Iram; Kim, Jun et al. (2008) Caspase-3 gene deletion prolongs survival in polycystic kidney disease. J Am Soc Nephrol 19:749-55

Showing the most recent 10 out of 79 publications